How do contextual factors influence naloxone distribution from syringe service programs in the USA: a cross-sectional study

Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone dis...

Full description

Saved in:
Bibliographic Details
Published inHarm reduction journal Vol. 20; no. 1; p. 26
Main Authors Lambdin, Barrot H, Wenger, Lynn, Bluthenthal, Ricky, Bartholomew, Tyler S, Tookes, Hansel E, LaKosky, Paul, O'Neill, Savannah, Kral, Alex H
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.02.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone distribution-they have staff and delivery models that are designed to reach people who use drugs where they are. We assessed which outer and inner setting factors of SSPs were associated with naloxone distribution in the USA. We surveyed SSPs in the USA known to the North American Syringe Exchange Network in 2019. Using the exploration, preparation, implementation and maintenance framework, we assessed inner and outer contextual factors associated with naloxone distribution among SSPs (n = 263 or 77% of SSPs). We utilized negative binomial regression to assess which factors were associated with the number of naloxone doses distributed and people receiving naloxone. SSPs reported distributing 710,232 naloxone doses to 230,506 people in the prior year. Regarding outer setting, SSPs located in areas with high levels of community support had a higher level of naloxone distribution (aIRR = 3.07; 95% confidence interval (CI): 2.09-4.51; p < 0.001) and 110% (p = 0.022) higher rate of people receiving naloxone (aIRR = 2.10; 95% CI 1.46-3.02; p < 0.001) in the past 12 months. The legal status of SSPs and the level of need was not significantly associated with naloxone distribution. Regarding inner setting, SSPs with proactive refill systems (aIRR = 2.08; 95% CI 1.27-3.41; p = 0.004), greater number of distribution days (aIRR = 1.09 per day; 95% CI 1.06-1.11; p < 0.001) and older programs (aIRR = 1.06 per year; 95% CI 1.02-1.11; p = 0.004) were associated with higher levels of naloxone distribution. Also, SSPs with proactive refill systems (aIRR = 2.23; 95% CI 1.38-3.58; p = 0.001); greater number of distribution days (aIRR = 1.04; 95% CI 1.02-1.07; p < 0.001) and older programs (aIRR = 1.11; 95% CI 1.05-1.17; p < 0.001) were associated with a higher number of people receiving naloxone. We identified outer and inner setting factors of SSPs that were associated with greater naloxone distribution. It is critical to ensure SSPs are adequately resourced to build community support for services and develop service delivery models that maximize naloxone distribution to address the nation's opioid overdose crisis.
AbstractList BACKGROUNDNaloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone distribution-they have staff and delivery models that are designed to reach people who use drugs where they are. We assessed which outer and inner setting factors of SSPs were associated with naloxone distribution in the USA. METHODSWe surveyed SSPs in the USA known to the North American Syringe Exchange Network in 2019. Using the exploration, preparation, implementation and maintenance framework, we assessed inner and outer contextual factors associated with naloxone distribution among SSPs (n = 263 or 77% of SSPs). We utilized negative binomial regression to assess which factors were associated with the number of naloxone doses distributed and people receiving naloxone. RESULTSSSPs reported distributing 710,232 naloxone doses to 230,506 people in the prior year. Regarding outer setting, SSPs located in areas with high levels of community support had a higher level of naloxone distribution (aIRR = 3.07; 95% confidence interval (CI): 2.09-4.51; p < 0.001) and 110% (p = 0.022) higher rate of people receiving naloxone (aIRR = 2.10; 95% CI 1.46-3.02; p < 0.001) in the past 12 months. The legal status of SSPs and the level of need was not significantly associated with naloxone distribution. Regarding inner setting, SSPs with proactive refill systems (aIRR = 2.08; 95% CI 1.27-3.41; p = 0.004), greater number of distribution days (aIRR = 1.09 per day; 95% CI 1.06-1.11; p < 0.001) and older programs (aIRR = 1.06 per year; 95% CI 1.02-1.11; p = 0.004) were associated with higher levels of naloxone distribution. Also, SSPs with proactive refill systems (aIRR = 2.23; 95% CI 1.38-3.58; p = 0.001); greater number of distribution days (aIRR = 1.04; 95% CI 1.02-1.07; p < 0.001) and older programs (aIRR = 1.11; 95% CI 1.05-1.17; p < 0.001) were associated with a higher number of people receiving naloxone. CONCLUSIONWe identified outer and inner setting factors of SSPs that were associated with greater naloxone distribution. It is critical to ensure SSPs are adequately resourced to build community support for services and develop service delivery models that maximize naloxone distribution to address the nation's opioid overdose crisis.
Abstract Background Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone distribution—they have staff and delivery models that are designed to reach people who use drugs where they are. We assessed which outer and inner setting factors of SSPs were associated with naloxone distribution in the USA. Methods We surveyed SSPs in the USA known to the North American Syringe Exchange Network in 2019. Using the exploration, preparation, implementation and maintenance framework, we assessed inner and outer contextual factors associated with naloxone distribution among SSPs (n = 263 or 77% of SSPs). We utilized negative binomial regression to assess which factors were associated with the number of naloxone doses distributed and people receiving naloxone. Results SSPs reported distributing 710,232 naloxone doses to 230,506 people in the prior year. Regarding outer setting, SSPs located in areas with high levels of community support had a higher level of naloxone distribution (aIRR = 3.07; 95% confidence interval (CI): 2.09–4.51; p < 0.001) and 110% (p = 0.022) higher rate of people receiving naloxone (aIRR = 2.10; 95% CI 1.46–3.02; p < 0.001) in the past 12 months. The legal status of SSPs and the level of need was not significantly associated with naloxone distribution. Regarding inner setting, SSPs with proactive refill systems (aIRR = 2.08; 95% CI 1.27–3.41; p = 0.004), greater number of distribution days (aIRR = 1.09 per day; 95% CI 1.06–1.11; p < 0.001) and older programs (aIRR = 1.06 per year; 95% CI 1.02–1.11; p = 0.004) were associated with higher levels of naloxone distribution. Also, SSPs with proactive refill systems (aIRR = 2.23; 95% CI 1.38–3.58; p = 0.001); greater number of distribution days (aIRR = 1.04; 95% CI 1.02–1.07; p < 0.001) and older programs (aIRR = 1.11; 95% CI 1.05–1.17; p < 0.001) were associated with a higher number of people receiving naloxone. Conclusion We identified outer and inner setting factors of SSPs that were associated with greater naloxone distribution. It is critical to ensure SSPs are adequately resourced to build community support for services and develop service delivery models that maximize naloxone distribution to address the nation’s opioid overdose crisis.
Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone distribution-they have staff and delivery models that are designed to reach people who use drugs where they are. We assessed which outer and inner setting factors of SSPs were associated with naloxone distribution in the USA. We surveyed SSPs in the USA known to the North American Syringe Exchange Network in 2019. Using the exploration, preparation, implementation and maintenance framework, we assessed inner and outer contextual factors associated with naloxone distribution among SSPs (n = 263 or 77% of SSPs). We utilized negative binomial regression to assess which factors were associated with the number of naloxone doses distributed and people receiving naloxone. SSPs reported distributing 710,232 naloxone doses to 230,506 people in the prior year. Regarding outer setting, SSPs located in areas with high levels of community support had a higher level of naloxone distribution (aIRR = 3.07; 95% confidence interval (CI): 2.09-4.51; p < 0.001) and 110% (p = 0.022) higher rate of people receiving naloxone (aIRR = 2.10; 95% CI 1.46-3.02; p < 0.001) in the past 12 months. The legal status of SSPs and the level of need was not significantly associated with naloxone distribution. Regarding inner setting, SSPs with proactive refill systems (aIRR = 2.08; 95% CI 1.27-3.41; p = 0.004), greater number of distribution days (aIRR = 1.09 per day; 95% CI 1.06-1.11; p < 0.001) and older programs (aIRR = 1.06 per year; 95% CI 1.02-1.11; p = 0.004) were associated with higher levels of naloxone distribution. Also, SSPs with proactive refill systems (aIRR = 2.23; 95% CI 1.38-3.58; p = 0.001); greater number of distribution days (aIRR = 1.04; 95% CI 1.02-1.07; p < 0.001) and older programs (aIRR = 1.11; 95% CI 1.05-1.17; p < 0.001) were associated with a higher number of people receiving naloxone. We identified outer and inner setting factors of SSPs that were associated with greater naloxone distribution. It is critical to ensure SSPs are adequately resourced to build community support for services and develop service delivery models that maximize naloxone distribution to address the nation's opioid overdose crisis.
Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone distribution--they have staff and delivery models that are designed to reach people who use drugs where they are. We assessed which outer and inner setting factors of SSPs were associated with naloxone distribution in the USA. We surveyed SSPs in the USA known to the North American Syringe Exchange Network in 2019. Using the exploration, preparation, implementation and maintenance framework, we assessed inner and outer contextual factors associated with naloxone distribution among SSPs (n = 263 or 77% of SSPs). We utilized negative binomial regression to assess which factors were associated with the number of naloxone doses distributed and people receiving naloxone. SSPs reported distributing 710,232 naloxone doses to 230,506 people in the prior year. Regarding outer setting, SSPs located in areas with high levels of community support had a higher level of naloxone distribution (aIRR = 3.07; 95% confidence interval (CI): 2.09-4.51; p < 0.001) and 110% (p = 0.022) higher rate of people receiving naloxone (aIRR = 2.10; 95% CI 1.46-3.02; p < 0.001) in the past 12 months. The legal status of SSPs and the level of need was not significantly associated with naloxone distribution. Regarding inner setting, SSPs with proactive refill systems (aIRR = 2.08; 95% CI 1.27-3.41; p = 0.004), greater number of distribution days (aIRR = 1.09 per day; 95% CI 1.06-1.11; p < 0.001) and older programs (aIRR = 1.06 per year; 95% CI 1.02-1.11; p = 0.004) were associated with higher levels of naloxone distribution. Also, SSPs with proactive refill systems (aIRR = 2.23; 95% CI 1.38-3.58; p = 0.001); greater number of distribution days (aIRR = 1.04; 95% CI 1.02-1.07; p < 0.001) and older programs (aIRR = 1.11; 95% CI 1.05-1.17; p < 0.001) were associated with a higher number of people receiving naloxone. We identified outer and inner setting factors of SSPs that were associated with greater naloxone distribution. It is critical to ensure SSPs are adequately resourced to build community support for services and develop service delivery models that maximize naloxone distribution to address the nation's opioid overdose crisis.
Background Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone distribution--they have staff and delivery models that are designed to reach people who use drugs where they are. We assessed which outer and inner setting factors of SSPs were associated with naloxone distribution in the USA. Methods We surveyed SSPs in the USA known to the North American Syringe Exchange Network in 2019. Using the exploration, preparation, implementation and maintenance framework, we assessed inner and outer contextual factors associated with naloxone distribution among SSPs (n = 263 or 77% of SSPs). We utilized negative binomial regression to assess which factors were associated with the number of naloxone doses distributed and people receiving naloxone. Results SSPs reported distributing 710,232 naloxone doses to 230,506 people in the prior year. Regarding outer setting, SSPs located in areas with high levels of community support had a higher level of naloxone distribution (aIRR = 3.07; 95% confidence interval (CI): 2.09-4.51; p < 0.001) and 110% (p = 0.022) higher rate of people receiving naloxone (aIRR = 2.10; 95% CI 1.46-3.02; p < 0.001) in the past 12 months. The legal status of SSPs and the level of need was not significantly associated with naloxone distribution. Regarding inner setting, SSPs with proactive refill systems (aIRR = 2.08; 95% CI 1.27-3.41; p = 0.004), greater number of distribution days (aIRR = 1.09 per day; 95% CI 1.06-1.11; p < 0.001) and older programs (aIRR = 1.06 per year; 95% CI 1.02-1.11; p = 0.004) were associated with higher levels of naloxone distribution. Also, SSPs with proactive refill systems (aIRR = 2.23; 95% CI 1.38-3.58; p = 0.001); greater number of distribution days (aIRR = 1.04; 95% CI 1.02-1.07; p < 0.001) and older programs (aIRR = 1.11; 95% CI 1.05-1.17; p < 0.001) were associated with a higher number of people receiving naloxone. Conclusion We identified outer and inner setting factors of SSPs that were associated with greater naloxone distribution. It is critical to ensure SSPs are adequately resourced to build community support for services and develop service delivery models that maximize naloxone distribution to address the nation's opioid overdose crisis. Keywords: Syringe services programs, Opioid overdose, Naloxone distribution, Implementation science
Abstract Background Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a range of evidence-based interventions in the USA, including naloxone distribution. Attributes of SSPs make them ideal settings for naloxone distribution—they have staff and delivery models that are designed to reach people who use drugs where they are. We assessed which outer and inner setting factors of SSPs were associated with naloxone distribution in the USA. Methods We surveyed SSPs in the USA known to the North American Syringe Exchange Network in 2019. Using the exploration, preparation, implementation and maintenance framework, we assessed inner and outer contextual factors associated with naloxone distribution among SSPs ( n  = 263 or 77% of SSPs). We utilized negative binomial regression to assess which factors were associated with the number of naloxone doses distributed and people receiving naloxone. Results SSPs reported distributing 710,232 naloxone doses to 230,506 people in the prior year. Regarding outer setting, SSPs located in areas with high levels of community support had a higher level of naloxone distribution (aIRR = 3.07; 95% confidence interval (CI): 2.09–4.51; p  < 0.001) and 110% ( p  = 0.022) higher rate of people receiving naloxone (aIRR = 2.10; 95% CI 1.46–3.02; p  < 0.001) in the past 12 months. The legal status of SSPs and the level of need was not significantly associated with naloxone distribution. Regarding inner setting, SSPs with proactive refill systems (aIRR = 2.08; 95% CI 1.27–3.41; p  = 0.004), greater number of distribution days (aIRR = 1.09 per day; 95% CI 1.06–1.11; p  < 0.001) and older programs (aIRR = 1.06 per year; 95% CI 1.02–1.11; p  = 0.004) were associated with higher levels of naloxone distribution. Also, SSPs with proactive refill systems (aIRR = 2.23; 95% CI 1.38–3.58; p  = 0.001); greater number of distribution days (aIRR = 1.04; 95% CI 1.02–1.07; p  < 0.001) and older programs (aIRR = 1.11; 95% CI 1.05–1.17; p  < 0.001) were associated with a higher number of people receiving naloxone. Conclusion We identified outer and inner setting factors of SSPs that were associated with greater naloxone distribution. It is critical to ensure SSPs are adequately resourced to build community support for services and develop service delivery models that maximize naloxone distribution to address the nation’s opioid overdose crisis.
ArticleNumber 26
Audience Academic
Author Bartholomew, Tyler S
Kral, Alex H
O'Neill, Savannah
Tookes, Hansel E
Bluthenthal, Ricky
LaKosky, Paul
Lambdin, Barrot H
Wenger, Lynn
Author_xml – sequence: 1
  givenname: Barrot H
  surname: Lambdin
  fullname: Lambdin, Barrot H
  email: blambdin@rti.org, blambdin@rti.org, blambdin@rti.org
  organization: University of Washington, Seattle, WA, USA. blambdin@rti.org
– sequence: 2
  givenname: Lynn
  surname: Wenger
  fullname: Wenger, Lynn
  organization: RTI International, Berkeley, CA, USA
– sequence: 3
  givenname: Ricky
  surname: Bluthenthal
  fullname: Bluthenthal, Ricky
  organization: University of Southern California, Los Angeles, CA, USA
– sequence: 4
  givenname: Tyler S
  surname: Bartholomew
  fullname: Bartholomew, Tyler S
  organization: University of Miami, Miami, FL, USA
– sequence: 5
  givenname: Hansel E
  surname: Tookes
  fullname: Tookes, Hansel E
  organization: University of Miami, Miami, FL, USA
– sequence: 6
  givenname: Paul
  surname: LaKosky
  fullname: LaKosky, Paul
  organization: North American Syringe Exchange Network, Tacoma, WA, USA
– sequence: 7
  givenname: Savannah
  surname: O'Neill
  fullname: O'Neill, Savannah
  organization: National Harm Reduction Coalition, Oakland, CA, USA
– sequence: 8
  givenname: Alex H
  surname: Kral
  fullname: Kral, Alex H
  organization: RTI International, Berkeley, CA, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36855181$$D View this record in MEDLINE/PubMed
BookMark eNptUltvFCEUnpgae9E_4IMh8cWXqVwH8MFk06ht0sQH7TNhgNmymYEVmNqNf152t9auMYRADt8lh_OdNkchBtc0rxE8R0h07zPCktEWYtJCyBlr6bPmBFHOW84QP3pyP25Oc15BWPFEvGiOSScYQwKdNL8u409gIzAxFHdfZj2CQZsSUwY-DOPsgnEg6DHeV29gfS7J93PxMYAhxQnkTfJh6UB26c5X6DrFZdLTlg3KrQM33xYfgAYmxZzb7MyWWT1yme3mZfN80GN2rx7Os-bm86fvF5ft9dcvVxeL69awjpRW4KEjmltp65YdosxijDpHjdZcMimcoEL2PaOWIIk4xj0lmCEKu95iI8lZc7XXtVGv1Dr5SaeNitqrXSGmpdKpeDM6xa0T1ayHmGtqGRTGiN6KgUhOLGSkan3ca63nfnLWuFCSHg9ED1-Cv1XLeKek5LiTogq8exBI8cfsclGTz8aNow4uzllhLhBGmDFWoW__ga7inOr37VC1adph8Re11LWBOrRYfc1WVC04kZB3nG61zv-Dqsu6ydfhu8HX-gEB7wm70SU3PPaIoNrGT-3jp2r81C5-ilbSm6e_80j5kzfyG5F911U
CitedBy_id crossref_primary_10_1016_j_drugpo_2023_104107
crossref_primary_10_1186_s12954_024_00995_y
crossref_primary_10_1186_s13012_024_01354_y
crossref_primary_10_1016_j_drugpo_2024_104456
crossref_primary_10_1016_j_drugpo_2023_104289
crossref_primary_10_1016_j_drugpo_2024_104462
crossref_primary_10_1016_j_peptides_2024_171268
Cites_doi 10.1016/j.trsl.2021.03.011
10.1111/add.13265
10.1111/add.13778
10.1371/journal.pone.0216205
10.1186/s40621-015-0041-8
10.1016/S0140-6736(18)33065-4
10.1186/s40352-019-0100-2
10.1136/bmj.f174
10.1080/10826080600669579
10.1186/s13012-018-0842-6
10.1016/j.jsat.2006.11.002
10.1186/s12954-022-00604-w
10.1007/s10488-010-0327-7
10.1016/j.geoforum.2007.03.012
10.1016/j.drugpo.2019.04.006
10.1016/S0002-9440(10)63747-9
10.1016/j.drugpo.2017.11.017
10.1016/j.drugalcdep.2021.108759
10.15585/mmwr.mm6911a4
10.1016/j.drugalcdep.2018.04.004
10.1016/0735-6757(94)90033-7
10.2105/AJPH.2014.302062
10.15585/mmwr.mm655051e1
10.15585/mmwr.mm7006a4
10.1080/08897077.2015.1132294
10.1016/S2468-2667(21)00304-2
10.2105/AJPH.2005.065961
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
ATCPS
AZQEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
PATMY
PIMPY
PQEST
PQQKQ
PQUKI
PYCSY
7X8
5PM
DOA
DOI 10.1186/s12954-023-00755-4
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Agriculture & Environmental Science Database
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Environmental Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Agricultural & Environmental Science Collection
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Publicly Available Content Database


CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
EISSN 1477-7517
EndPage 26
ExternalDocumentID oai_doaj_org_article_7de863ab027a4d508cc8bd8f3973d053
A739076745
10_1186_s12954_023_00755_4
36855181
Genre Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: R01 DA046867
– fundername: ;
  grantid: 5R01DA046867; 5R01DA046867; 5R01DA046867; 5R01DA046867; 5R01DA046867; 5R01DA046867
GroupedDBID ---
-A0
0R~
29I
2WC
2XV
3V.
53G
5GY
5VS
7X7
7XC
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACHQT
ACIHN
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AFKRA
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPY
ITC
KQ8
M1P
M48
M~E
NPM
O5R
O5S
OK1
P2P
PATMY
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
AAYXX
AFPKN
CITATION
ABVAZ
AFGXO
AFNRJ
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c563t-82f63a7d9d7d996145d2216e4caa79598e8489bb54d3191722b43251406bd2c93
IEDL.DBID RPM
ISSN 1477-7517
IngestDate Tue Oct 22 15:05:55 EDT 2024
Tue Sep 17 21:32:02 EDT 2024
Sat Oct 05 05:36:53 EDT 2024
Thu Oct 10 21:07:18 EDT 2024
Fri Feb 23 00:08:25 EST 2024
Fri Feb 02 04:33:56 EST 2024
Thu Sep 12 18:56:41 EDT 2024
Wed Oct 16 00:39:06 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Opioid overdose
Implementation science
Syringe services programs
Naloxone distribution
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-82f63a7d9d7d996145d2216e4caa79598e8489bb54d3191722b43251406bd2c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972698/
PMID 36855181
PQID 2788484628
PQPubID 105462
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_7de863ab027a4d508cc8bd8f3973d053
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9972698
proquest_miscellaneous_2781212555
proquest_journals_2788484628
gale_infotracmisc_A739076745
gale_infotracacademiconefile_A739076745
crossref_primary_10_1186_s12954_023_00755_4
pubmed_primary_36855181
PublicationCentury 2000
PublicationDate 2023-02-28
PublicationDateYYYYMMDD 2023-02-28
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Harm reduction journal
PublicationTitleAlternate Harm Reduct J
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 755_CR5
755_CR6
A Wodak (755_CR13) 2006; 41
BH Lambdin (755_CR16) 2018; 52
CL Mattson (755_CR4) 2021; 70
EL Winstanley (755_CR20) 2016; 37
B Tempalski (755_CR29) 2007; 97
AS Bennett (755_CR19) 2022; 19
AY Walley (755_CR25) 2013; 346
EN Kinnard (755_CR18) 2021; 225
EH Teshale (755_CR36) 2019; 14
RA Rudd (755_CR1) 2016; 65
CM Jones (755_CR31) 2019; 70
N Wilson (755_CR2) 2020; 69
SM Bird (755_CR26) 2019; 393
CS Davis (755_CR10) 2014; 104
755_CR32
755_CR11
B Lambdin (755_CR35) 2022; 17
B Tempalski (755_CR28) 2007; 38
WJ Ferguson (755_CR39) 2019; 7
KG Heinzerling (755_CR14) 2007; 32
755_CR17
SM Bird (755_CR27) 2016; 111
755_CR37
755_CR12
BH Lambdin (755_CR34) 2018; 188
Centers for Disease Control and Prevention (755_CR40) 2010; 59
GA Aarons (755_CR22) 2011; 38
RE Giglio (755_CR9) 2015; 2
JC Moullin (755_CR24) 2019; 14
JM Chamberlain (755_CR7) 1994; 12
(755_CR23) 2012
H Hedegaard (755_CR3) 2020; 356
DC Perlman (755_CR15) 1997; 87
C Michiels (755_CR8) 2004; 164
LD Wenger (755_CR38) 2021; 234
L Black (755_CR21) 2017; 112
MA Irvine (755_CR30) 2022; 7
BH Lambdin (755_CR33) 2022; 17
References_xml – volume: 234
  start-page: 159
  year: 2021
  ident: 755_CR38
  publication-title: Transl Res
  doi: 10.1016/j.trsl.2021.03.011
  contributor:
    fullname: LD Wenger
– ident: 755_CR6
– ident: 755_CR11
– volume: 87
  start-page: 862
  issue: 5
  year: 1997
  ident: 755_CR15
  publication-title: Am J Public Health
  contributor:
    fullname: DC Perlman
– ident: 755_CR17
– volume: 111
  start-page: 883
  issue: 5
  year: 2016
  ident: 755_CR27
  publication-title: Addiction
  doi: 10.1111/add.13265
  contributor:
    fullname: SM Bird
– ident: 755_CR32
– volume: 112
  start-page: 911
  issue: 5
  year: 2017
  ident: 755_CR21
  publication-title: Addiction
  doi: 10.1111/add.13778
  contributor:
    fullname: L Black
– volume: 14
  issue: 4
  year: 2019
  ident: 755_CR36
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0216205
  contributor:
    fullname: EH Teshale
– volume: 2
  start-page: 10
  issue: 1
  year: 2015
  ident: 755_CR9
  publication-title: Inj Epidemiol
  doi: 10.1186/s40621-015-0041-8
  contributor:
    fullname: RE Giglio
– volume: 393
  start-page: 316
  issue: 10169
  year: 2019
  ident: 755_CR26
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)33065-4
  contributor:
    fullname: SM Bird
– volume: 7
  start-page: 19
  issue: 1
  year: 2019
  ident: 755_CR39
  publication-title: Health Justice
  doi: 10.1186/s40352-019-0100-2
  contributor:
    fullname: WJ Ferguson
– volume: 59
  start-page: 1488
  issue: 45
  year: 2010
  ident: 755_CR40
  publication-title: MMWR Morb Mortal Wkly Rep
  contributor:
    fullname: Centers for Disease Control and Prevention
– volume: 346
  year: 2013
  ident: 755_CR25
  publication-title: BMJ
  doi: 10.1136/bmj.f174
  contributor:
    fullname: AY Walley
– volume: 41
  start-page: 777
  issue: 6–7
  year: 2006
  ident: 755_CR13
  publication-title: Subst Use Misuse
  doi: 10.1080/10826080600669579
  contributor:
    fullname: A Wodak
– volume: 14
  start-page: 1
  issue: 1
  year: 2019
  ident: 755_CR24
  publication-title: Implement Sci
  doi: 10.1186/s13012-018-0842-6
  contributor:
    fullname: JC Moullin
– volume: 17
  start-page: 1
  issue: SUPPL 1
  year: 2022
  ident: 755_CR35
  publication-title: Implement Sci
  contributor:
    fullname: B Lambdin
– volume: 32
  start-page: 423
  issue: 4
  year: 2007
  ident: 755_CR14
  publication-title: J Subst Abuse Treat
  doi: 10.1016/j.jsat.2006.11.002
  contributor:
    fullname: KG Heinzerling
– volume: 19
  start-page: 20
  issue: 1
  year: 2022
  ident: 755_CR19
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-022-00604-w
  contributor:
    fullname: AS Bennett
– volume: 38
  start-page: 4
  issue: 1
  year: 2011
  ident: 755_CR22
  publication-title: Adm Policy Ment Health
  doi: 10.1007/s10488-010-0327-7
  contributor:
    fullname: GA Aarons
– volume: 38
  start-page: 1250
  issue: 6
  year: 2007
  ident: 755_CR28
  publication-title: Geoforum
  doi: 10.1016/j.geoforum.2007.03.012
  contributor:
    fullname: B Tempalski
– ident: 755_CR5
– ident: 755_CR12
– ident: 755_CR37
– volume-title: Dissemination and implementation research in health: translating science to practice
  year: 2012
  ident: 755_CR23
– volume: 70
  start-page: 22
  year: 2019
  ident: 755_CR31
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2019.04.006
  contributor:
    fullname: CM Jones
– volume: 17
  start-page: 1
  issue: SUPPL 1
  year: 2022
  ident: 755_CR33
  publication-title: Implement Sci
  contributor:
    fullname: BH Lambdin
– volume: 164
  start-page: 1875
  issue: 6
  year: 2004
  ident: 755_CR8
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)63747-9
  contributor:
    fullname: C Michiels
– volume: 52
  start-page: 52
  year: 2018
  ident: 755_CR16
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2017.11.017
  contributor:
    fullname: BH Lambdin
– volume: 225
  year: 2021
  ident: 755_CR18
  publication-title: CA Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2021.108759
  contributor:
    fullname: EN Kinnard
– volume: 69
  start-page: 290
  issue: 11
  year: 2020
  ident: 755_CR2
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6911a4
  contributor:
    fullname: N Wilson
– volume: 188
  start-page: 370
  year: 2018
  ident: 755_CR34
  publication-title: Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2018.04.004
  contributor:
    fullname: BH Lambdin
– volume: 12
  start-page: 650
  issue: 6
  year: 1994
  ident: 755_CR7
  publication-title: Am J Emerg Med
  doi: 10.1016/0735-6757(94)90033-7
  contributor:
    fullname: JM Chamberlain
– volume: 104
  start-page: e7
  issue: 8
  year: 2014
  ident: 755_CR10
  publication-title: Am J Public Health
  doi: 10.2105/AJPH.2014.302062
  contributor:
    fullname: CS Davis
– volume: 65
  start-page: 1445
  issue: 50–51
  year: 2016
  ident: 755_CR1
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm655051e1
  contributor:
    fullname: RA Rudd
– volume: 356
  start-page: 1
  year: 2020
  ident: 755_CR3
  publication-title: NCHS Data Brief
  contributor:
    fullname: H Hedegaard
– volume: 70
  start-page: 202
  issue: 6
  year: 2021
  ident: 755_CR4
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm7006a4
  contributor:
    fullname: CL Mattson
– volume: 37
  start-page: 42
  issue: 1
  year: 2016
  ident: 755_CR20
  publication-title: Subst Abuse
  doi: 10.1080/08897077.2015.1132294
  contributor:
    fullname: EL Winstanley
– volume: 7
  start-page: e210
  issue: 3
  year: 2022
  ident: 755_CR30
  publication-title: Lancet Public Health
  doi: 10.1016/S2468-2667(21)00304-2
  contributor:
    fullname: MA Irvine
– volume: 97
  start-page: 437
  issue: 3
  year: 2007
  ident: 755_CR29
  publication-title: Am J Public Health
  doi: 10.2105/AJPH.2005.065961
  contributor:
    fullname: B Tempalski
SSID ssj0029538
Score 2.3970928
Snippet Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that provide a...
Abstract Background Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention...
Background Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that...
BackgroundNaloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that...
BACKGROUNDNaloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention programs that...
Abstract Background Naloxone is a medication that can quickly reverse an opioid overdose. Syringe service programs (SSPs) are community-based prevention...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 26
SubjectTerms Community involvement
Confidence intervals
Consent
Cross-Sectional Studies
Distribution
Dosage and administration
Drug dosages
Drug overdose
Drug Overdose - prevention & control
Drug use
Drugs
Electronic mail systems
Evidence-based medicine
Fatalities
Harm reduction
Humans
Implementation science
Intervention
Methods
Mortality
Naloxone
Naloxone - therapeutic use
Naloxone distribution
Narcotics
Opiate Overdose
Opioid overdose
Opioids
Overdose
Participation
Prevention programs
Review boards
Social support
Statistical analysis
Syringe services programs
Syringes
United States
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LitRAsJE9eRHfRkdpQfQgzW76lY63UVwGQS86uLemX4OLkshkBl38-a3qdIYJHrx4CIT0g-56dFWl60HIC-5U4lElJmIdmGw2jvmk4S24qLk_Szp7VX78pFdr-eFCXRyV-kKfsDE98Ai40yYmo4XzYD45GUGdCMH4aDYgR0UECsqnb60mY6qYWi3w8RQiY_TpUON1FgP5xFBGKiZnYihn6__7TD4SSnOHySMJdH6b3CqqI12OS75DbqTuLlmM8bX0a_qxcdtEX9LpQ7_9fo_8WfW_aOwpeqTDMbyHhlJhh15O5UkozNr_7rtEI2bRLQWwKAae0OEq__ejw3ik0OLOhaMpqI50_Xn5hjqaN8mG7NaFa8xJa--T9fn7L-9WrNRbYEFpsWOGbwDSTWwjPC3IbRU5r3UCvDksSW6Skab1Xsko0Mzj3EsB-hHoBD7y0IoH5KSD1T4iFOxe1yZQLYMwMtUg8owKTWpgRryaDRV5PYHf_hzTathsjhhtR2RZQJbNyLKyIm8RQ4eemBI7fwBCsYVQ7L8IpSKvEL8WGReQGFyJP4AFYwosu2xEe4apjVRFFrOewHBh3jxRiC0MP1jeGAAOBvpW5PmhGUeiE1uX-n3uU4OmoBRM8XAkqMOWsA6AAm2rIs2M1GZ7nrd0l99yOnAMfdatefw_gPSE3OSZSzBmf0FOdtt9egpa184_ywx2DWTWKmE
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1Ni9QwNOjuxYv4bXWUCKIHCbvNV1MvMiu7DIKLqIN7C2mS0UVp1-kMKv5530vTcYvgYWBo0vDS9528D0KecqciDyoyEUrPZLVyrIka_nkXNG8Oo05RlW9P9WIp35yps3zg1uewylEmJkEdOo9n5AccfDVpMJPy1cV3hl2j8HY1t9C4SvZ5KfGadv_o-PTd-53LVQM_j6kyRh_0JV5rMdBTDHWlYnKijlLV_n9l8yXlNA2cvKSJTm6Q69mEpPMB5zfJldjeIrMhz5Z-it9Wbh3pMzo-6NZfb5Pfi-4HDR3FyHQQx1sYyJ126PnYpoTCqt3Pro00YDXd3AiLYgIK7X-l8z_aD6KF5rAufJuCCUmXH-YvqaNpk6xP4V0IYypee4csT44_vl6w3HeBeaXFhhm-0sJVoQ7wq0F_q8B5qSPgz2FrchMBE3XTKBkEunucN1KAnQS2QRO4r8VdstcCtPcJBf_X1RFMTC-MjCWoPqN8FStYEa9ofUFejJ_fXgzlNWxyS4y2A7IsIMsmZFlZkCPE0G4mlsZOD7r1Z5s5zVYhGgC_AX_byQD2p_emCWYFhpcIIHIK8hzxa5GBAYne5TwEABhLYdl5JepDLHGkCjKbzATG89PhkUJsZvze_iXTgjzZDeObGMzWxm6b5pRgMSgFS9wbCGq3JewHoMDqKkg1IbXJnqcj7fmXVBYcU6B1bR78H6yH5BpP9I9Z-TOyt1lv4yOwqzbN48w8fwDUniM_
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1da9RAcKn1xRfx29SzrCD6IKvNfmUjSDnFcgj1RQ_7tmx297S0JJrcYYt_3plNcjRYfAiE7AezOzM7M9n5IOQ5dyryoCITIfdMFivHqqjhzbugeXUQdfKqPP6sF0v56USd7JCx3NGwgd21ph3Wk1q2568vfl0eAsO_Swxv9Jsux8sqBtKHoQRUTN4gN7kUEin-WG5vFaCXMGPgzLXjJsIp5fD_96S-IqqmbpRX5NLRHXJ7UCjpvKeAu2Qn1vfIrI-6pd_i-cq1kb6g44emPbtP_iya3zQ0FP3U4XDeQMNQd4eejkVLKMzaXDR1pAFz6w5lsSiGo9DuMv0NpF1_0NDByQtHU1Ao6fLL_C11NC2SdcnZC2FMqWwfkOXRx68fFmyowsC80mLNDF9p4YpQBnhKkOYqcJ7rCNh0WKjcRCNNWVVKBoHGH-eVFKA1gaZQBe5L8ZDs1gDtY0LBGnZlBIXTCyNjDoLQKF_EAmbEC1ufkVfj9tuffbINm4wUo22PLAvIsglZVmbkPWJo2xMTZacPTfvdDnxnixANgF-B9e1kAG3Ue1MFswI1TAQ4gDLyEvFrkcAAid4NUQkAMCbGsvNClAeY8EhlZDbpCWzop80jhdiRii0vDGwOhv9m5Nm2GUeia1sdm03qk4P-oBRM8agnqO2SsDqAAh0sI8WE1CZrnrbUpz9SknAMiNal2fs_WE_ILZ7oH2P0Z2R33W7iU9Cy1tV-Yp2_DoklAQ
  priority: 102
  providerName: Scholars Portal
Title How do contextual factors influence naloxone distribution from syringe service programs in the USA: a cross-sectional study
URI https://www.ncbi.nlm.nih.gov/pubmed/36855181
https://www.proquest.com/docview/2788484628
https://search.proquest.com/docview/2781212555
https://pubmed.ncbi.nlm.nih.gov/PMC9972698
https://doaj.org/article/7de863ab027a4d508cc8bd8f3973d053
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtQw0GrLhQviTeiyMhKCA3K3sePY4batWq2QtqqAFXuzHNtbVrRJtQ8VxM8z4ySrRtw4JIrih8aZGc-MMw9C3nErA_cyMOFTxzK1sKwMOTw563NeHoc8elVOL_LJLPs8l_M9IrtYmOi078rlUXV9c1Qtf0TfytsbN-r8xEaX01MM9swLPdon-0qIzkRvrawCWLiLjtH5aJ3inywGoomheJQMK_Fg1nWZ6rQnjGLO_n935nuiqe82eU8OnT8mj1oFko4bQJ-QvVA9JYMmypZ-D9cLuwr0Pe1e1Kufz8ifSX1HfU3RLx024y00tHV26LIrUkJh1vpXXQXqMZduWwaLYvgJXf-Op3903WwstHXqwtEUFEg6-zr-RC2Ni2Tr6NyFMMbUtc_J7Pzs2-mEtVUXmJO52DDNF7mwyhcergKkt_Scp3kA7FksTK6DznRRljLzAo09zstMgJYEmkHpuSvEC3JQAbSvCAXr1xYBFEwndBZSEHxaOhUUzIg_aF1CPnaf39w2yTVMNEp0bhq8GcCbiXgzWUJOEEO7npgYO76oV1emJQ-jfNAAfgnWts08aJ_O6dLrBahdwsOGk5APiF-D7AtIdLaNQgCAMRGWGStRHGOCI5mQQa8nsJ3rN3cUYlq2XxuuNHwcDPdNyNtdM45EV7Yq1NvYJwV9QUqY4mVDULsldXSZENUjtd6a-y3AIzEpeMsTr_975CF5yCOXYLj-gBxsVtvwBhSuTTkENpurIXlwcnZx-WUYjy3gPs30MLLeX1N4Ly8
link.rule.ids 230,315,733,786,790,870,891,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1Nb9Mw1IJxgMvEN4ECRkJwQNYWfyQOF1QQU4FtF1bRm-XYLkxMyWhaAeLP857jdIuQOFSqYsd6zvu23wchz7lVgXsVmPC5Y7JcWlaHAv456wte74ciRlUeHRezufy4UIt04NalsMpBJkZB7VuHZ-R7HHw1qTGT8s35D4Zdo_B2NbXQuEquSSEk0nm5uHC4KuDmIVFGF3tdjpdaDLQUQ02pmBwpo1iz_1_JfEk1jcMmL-mhg5tkNxmQdNpj_Ba5EprbZNJn2dIv4WxpV4G-oMODdvX9Dvkza39S31KMSwdhvIGB1GeHng5NSiis2v5qm0A91tJNbbAopp_Q7nc8_aNdL1hoCurCtykYkHT-efqaWho3yboY3IUwxtK1d8n84P3JuxlLXReYU4VYM82XhbClrzz8KtDeynOeFwGwZ7ExuQ6Ah6qulfQCnT3OaynASgLLoPbcVeIe2WkA2geEgvdrqwAGphNahhwUn1auDCWsiBe0LiOvhs9vzvviGiY6JbowPbIMIMtEZBmZkbeIoe1MLIwdH7SrrybxmSl90AB-Dd62lR6sT-d07fUSzC7hQeBk5CXi1yD7AhKdTVkIADAWwjLTUlT7WOBIZWQymgls58bDA4WYxPaduSDSjDzbDuObGMrWhHYT5-RgLygFS9zvCWq7JewGoMDmykg5IrXRnscjzem3WBQcE6CLSj_8P1hPyfXZydGhOfxw_OkRucEjL2B-_oTsrFeb8BgsrHX9JLLRX8GnJMY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zj9MwELZgkRAv3EeWAkZC8IDcbJw4cXgrC1U5drUSVKz2xYqPstXuJlXTiuvPM-MkVQNv-1Cp8iU7_jyeSWa-IeQFL4TjVjgW28iwJJsVTLsU_pnCplzvudR7VR4cppNp8vFYHG-l-vJO-0bPh-X5xbCcn3rfysWFCTs_sfDoYB-DPdNchgs7C6-Sa3BmedYZ6q2tlUNhFyMj07CO8HsWgwuK4SUpGObjQe51EcmodyV55v7_5fPWBdV3nty6jca3yEm3jsYJ5Wy4Xumh-f0PxeOlFnqb3Gx1VDpqmtwhV1x5lwyaQF76zZ3PiqWjL2lXUC3P7pE_k-oHtRVF13eQ92uoaFP50HmXB4XCqNXPqnTUIl1vm2mLYoQLrX_5F4y0bmQXbf3GsDcFHZVOv4ze0IL6J8hq7z-Gc_TsuPfJdPz-6_6EtYkdmBFpvGKSz9K4yGxu4ZeDgiAs51HqACAF5j6XTiYy11okNkZ7knOdxKCIgfKhLTd5_IDslDDbR4SCgV3kDnRYE8vERXC3SmEyl8GI-A3YBOR1t7dq0fB3KG_3yFQ1oFAACuVBoZKAvMXt37RE7m1fUC2_q3ZjVGadhOlrMOiLxIKCa4zUVs5As4styLSAvELwKJQQgBBTtIEOMGHk2lKjLM73kENJBGTQawkn2_SrO_ipVrLUimcSHg5GFAfk-aYae6K3XOmqtW8TgUoiBAzxsEHrZkkd6AOS9XDcW3O_BtDpecdbNO5euuczcv3o3Vh9_nD46TG5wf1pRHKAAdlZLdfuCah3K_3UH-S_WdtPZw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=How+do+contextual+factors+influence+naloxone+distribution+from+syringe+service+programs+in+the+USA%3A+a+cross-sectional+study&rft.jtitle=Harm+reduction+journal&rft.au=Lambdin%2C+Barrot+H&rft.au=Wenger%2C+Lynn&rft.au=Bluthenthal%2C+Ricky&rft.au=Bartholomew%2C+Tyler+S&rft.date=2023-02-28&rft.pub=BioMed+Central&rft.eissn=1477-7517&rft.volume=20&rft.spage=1&rft_id=info:doi/10.1186%2Fs12954-023-00755-4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7517&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7517&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7517&client=summon